Walk in Drive for D.Pharm, B.Pharm, M.Pharm in Production and Quality at Granules India
11 July 2025

Walk in Drive for D.Pharm, B.Pharm, M.Pharm in Production and Quality at Granules India

Granules India is a vertically integrated, high-growth pharmaceutical company with 38 years of proven performance and increasing performance and increasing presence across the world.
11 July 2025
Aculife Healthcare looking for Research Scientist / Executive - M.Pharm Apply
PHARMACY GRADUATE WITH 3 TO 7 YEARS OF EXPERIENCE IN FORMULATION DEVELOPMENT OF STERILE DOSAGE FORMS AS PER GUIDELINES OF US, EU, CANADA, BRAZIL AND ROW MARKET.
11 July 2025
Hiring IPR Executive / Senior Executive at Apitoria Pharma - M.Pharm, MSc Apply
Candidate should have experience in the IP evaluation of APIs, Infringement analysis, FTO analysis and summary reports, patent searching, patent drafting, patent filing and patent prosecution.
11 July 2025
Glenmark and AbbVie sign USD 700 million drug licensing agreement
AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGIs lead investigational asset, ISB 2001, developed using IGIs proprietary BEAT protein platform, for oncology and autoimmune diseases
11 July 2025
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

Ascentage Pharma a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval

11 July 2025
Milestone Pharmaceuticals announces FDA acceptance of the Company’s Response to the CRL for CARDAMYST (etripamil) Nasal Spray

Milestone Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025.

10 July 2025
Opportunity for B.Pharm, MSc as JRF in Amity Institute of Virology and Immunology
B.S. 4 years programme , BPharm, MBBS, Integrated BS-MS, MSc, BE, BTech or equivalent degree, with 55% marks and passing of NET, GATE test.
10 July 2025
Ministry of Defence Hiring Pharmacists (04 posts)
B.Pharmacy / Diploma in Pharmacy and registered as Pharmacist under the Pharmacy Act 1948, Minimum 03 years Work Experience
10 July 2025
Pharmacy Apprentice under the Ministry of Power at NHPC Limited
A Direct Benefit Transfer (DBT) amount of Rs. 4000 for Diploma Apprentices will be provided by Govt. of India under NATS scheme. The above stipend is inclusive of DBT amount wherever applicable.
10 July 2025
Interview for B.Pharm, MSc as JRF at IIT Guwahati
Post Graduate degree in basic science M.Sc./ BE/ B.Tech/ B.VSc/ B.Pharm or Graduate / Post Graduate Degree in Professional Course.